Sugi Predict

Sugi Predict / Compounds / SCHEMBL351398

SCHEMBL351398

SCHEMBL351398

COC(=O)[C@H]1CC[C@@H](CO)CC1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 1/20 0.44
▸ ALDH1A1 P00352 3/20 0.42
▸ GAA P10253 1/20 0.42
▸ SMN1; SMN2 Q16637 4/20 0.42
▸ CHRNB2 P17787 2/20 0.39
▸ CHRNA4 P43681 2/20 0.39
▸ CHRNB4 P30926 1/20 0.39
▸ CHRNA3 P32297 1/20 0.39
▸ CHRNA7 P36544 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ HPGD P15428 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ PPM1B O75688 1/20 0.37
▸ PTPN1 P18031 1/20 0.37
▸ PPP1CC P36873 1/20 0.37
▸ HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL408809 1.00 TP53 (0.44) TP53ALDH1A1GAASMN1; SMN2CHRNB2
SCHEMBL351399 1.00 TP53 (0.44) TP53ALDH1A1GAASMN1; SMN2CHRNB2
SCHEMBL31196542 0.92 ALDH1A1 (0.45) TP53ALDH1A1GAASMN1; SMN2CHRNB2
SCHEMBL3288516 0.88 CHRNB2 (0.41) TP53ALDH1A1GAASMN1; SMN2CHRNB2
SCHEMBL1660232 0.88 CHRNB2 (0.41) TP53ALDH1A1GAASMN1; SMN2CHRNB2
SCHEMBL1660231 0.88 CHRNB2 (0.41) TP53ALDH1A1GAASMN1; SMN2CHRNB2
SCHEMBL14305169 0.84 TP53 (0.46) TP53ALDH1A1GAASMN1; SMN2CHRNB2
SCHEMBL358775 0.84 GAA (0.47) TP53ALDH1A1GAASMN1; SMN2CHRNB2
SCHEMBL17118123 0.84 TP53 (0.46) TP53ALDH1A1GAASMN1; SMN2CHRNB2
SCHEMBL5543322 0.84 GAA (0.47) TP53ALDH1A1GAASMN1; SMN2CHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025059577-A1 SUBSTITUTED AMINOPYRIDINE COMPOUNDS FOR USE AS AKT1 INHIBITORS ATAVISTIK BIO, INC. (US) 2025-03-20 — — WO disclosed
WO-2025026283-A1 COMPOUND FOR SELECTIVELY DEGRADING SMARCA2/4 AND USE THEREOF 甘李药业股份有限公司 2025-02-06 — — WO disclosed
WO-2024192064-A1 COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 DEGRADERS AND USES THEREOF ONCOPIA THERAPEUTICS, INC. D/B/A/ PROTEOVANT THERAPEUTICS, INC. (US) 2024-09-19 — — WO disclosed
US-20240016942-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-18 — — US disclosed
US-20240016942-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-18 — — US disclosed
US-20240016942-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-18 — — US disclosed
US-20230250096-A1 SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2023-08-10 — — US disclosed
EP-4121055-A1 STAT DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2023-01-25 — — EP disclosed
WO-2021188696-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-09-23 — — WO disclosed
EP-3388423-B1 NK1 RECEPTOR ANTAGONIST KISSEI PHARMACEUTICAL (JP) 2020-05-27 — — EP disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 — — US disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 — — US disclosed
CN-1976911-A Arylphenylamino-, arylphenylamide-and arylphenylether-thioether derivatives ICOS CORP (US) 2007-06-06 — — CN disclosed
EP-1740565-A2 ARYLPHENYLAMINO-, ARYLPHENYLAMIDE-, AND ARYLPHENYLETHER-SUFIDE DERIVATIVES ICOS Corporation (US) 2007-01-10 — — EP disclosed
US-20060293345-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. 2006-12-28 — — US disclosed
WO-2006128184-A2 PYRIMIDINE OR TRIAZINE FUSED BICYCLIC METALLOPROTEASE INHIBITORS ALANTOS-PHARMACEUTICALS, INC. (US) 2006-11-30 — — WO disclosed
US-7115741-B2 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds ALEXION PHARMACEUTICALS, INC. 2006-10-03 — — US disclosed
WO-2005105770-A2 ARYLPHENYLAMINO-, ARYLPHENYLAMIDE-, AND ARYLPHENYLETHER-SULFIDE DERIVATIVES ICOS CORPORATION (US) 2005-11-10 — — WO disclosed
US-20030153556-A1 Piperazine and homopiperazine compounds MILLENNIUM PHARMACEUTICALS, INC. 2003-08-14 — — US disclosed
WO-2003022214-A2 PIPERAZINE AND HOMOPIPERAZINE COMPOUNDS MILLENNIUM PHARMACEUTICALS, INC. (US) 2003-03-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030153556-A1 Piperazine and homopiperazine compounds HAMP, MPL, F2 TP53 3224/4885ALDH1A1 3346/4885GAA 4771/4885
US-20060293345-A1 Heterobicyclic metalloprotease inhibitors MMP13, MMP3, MMP10 TP53 3384/4885ALDH1A1 1873/4885GAA 287/4885
US-20240016942-A1 STAT DEGRADERS AND USES THEREOF STAT4, STAT1, STAT3 TP53 32/4885ALDH1A1 2465/4885GAA 312/4885
US-20230250096-A1 SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES MLLT1, BMI1, MEN1 TP53 107/4885ALDH1A1 2922/4885GAA 4129/4885
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 TP53 3627/4885ALDH1A1 1806/4885GAA 352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.